Tom

SECRETARY RUBIO: NATO wasn’t just about defending Europe, but allowing us to have military bases in Europe for our national security. If we’ve reached a point where the NATO alliance means that we can’t use those bases to defend our interests, then it’s a one-way street.

Rep. Rich McCormick: "We were horrible in Vietnam until we did Rolling Thunder One and Rolling Thunder Two, and then we won. As soon as we do half-measures, we lose. The faster we get this over the better. If we seize Kharg Island, it's technically boots on the ground. It could be done almost flawlessly. If we have enough firepower, it would be very easy to defend."

Hegseth indicates reopening the Strait of Hormuz is not a core US objective: "We've been willing to lead, President Trump has led the entire time, but it's not just us. You might want to start learning how to fight for yourself."

Hegseth: "The president was clear this morning in his Truth that there are countries around the world who ought to be prepared to step up on this critical waterway as well. Last time I checked there was supposed to be a big bad Royal Navy that could be prepared to do things like that."

A single dose of a new cancer drug made a brain tumor almost disappear – in just five days. Doctors at Massachusetts General Hospital reported “dramatic and rapid” tumor regression in the first patients treated with a next-generation form of CAR T-cell therapy for glioblastoma, one of the most aggressive brain cancers known. The therapy, called CARv3-TEAM-E, was developed to overcome a major hurdle in treating solid tumors: their ability to hide from the immune system. The personalized treatment reprograms a patient’s immune cells to attack the tumor, and in one extraordinary case, nearly eliminated the cancer within just five days. This novel therapy is designed to target multiple features of the tumor at once, a strategy that may help overcome the common challenge of treatment resistance in solid tumors like glioblastoma. Although the tumors eventually returned, the early outcomes were described as unprecedented. One patient saw a 60% reduction in tumor size that lasted for half a year—an impressive result in a cancer known for its aggressiveness. The trial’s success marks a major step forward for immunotherapy in brain cancer and raises new hopes for long-term control or even a cure. Researchers are now working to refine the treatment and extend its effects, with the ultimate goal of turning a once-terminal diagnosis into a survivable condition.

Esto parece de chiste... La empresa de ferrocarriles húngaros "se ha olvidado" de que esta noche era el cambio de hora... 😱😱😱 Bueno, la cosa es más complicada, claro, quien se ha olvidado es la empresa que desarrolló la aplicación informática, así que muestra todos los trenes